Inventor
HOUZE JONATHAN B
US27 patents
⚠️ This page may combine multiple inventors who share the name “HOUZE JONATHAN B”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
AMGEN INC
18 patentsUS7041691B1May 9, 2006
Compounds for the modulation of PPARγ activity
AMGEN INC38 citations96
US7439242B2Oct 21, 2008
PPARγ modulators
AMGEN INC14 citations91
US7968567B2Jun 28, 2011
Compounds for the modulation of PPARγ activity
AMGEN INC8 citations84
US7626033B2Dec 1, 2009
Compounds for the modulation of PPARγ activity
AMGEN INC12 citations84
US11608344B2Mar 21, 2023
Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
AMGEN INC4 citations83
US7582803B2Sep 1, 2009
Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders
AMGEN INC17 citations83
US11718617B2Aug 8, 2023
Heterocyclic compounds as triggering receptor expressed on myeloid cells2 agonists and methods of use
AMGEN INC4 citations73
US11912711B2Feb 27, 2024
Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
AMGEN INC3 citations72
US11884675B2Jan 30, 2024
Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
AMGEN INC3 citations72
US11306107B2Apr 19, 2022
Compounds that inhibit MCL-1 protein
AMGEN INC2 citations71
US7060718B2Jun 13, 2006
Arylsulfonanilide ureas
AMGEN INC1 citations63
US7960408B2Jun 14, 2011
Quinolinyl and benzothiazolyl modulators
AMGEN INC4 citations62
US7687526B2Mar 30, 2010
Benzo-fused compounds for use in treating metabolic disorders
AMGEN INC5 citations62
US12319691B2Jun 3, 2025
Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
AMGEN INC0 citations61
US12252489B2Mar 18, 2025
Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
AMGEN INC0 citations61
US12428425B2Sep 30, 2025
Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
AMGEN INC0 citations60
US8003648B2Aug 23, 2011
Heterocyclic GPR40 modulators
AMGEN INC1 citations50
US7714008B2May 11, 2010
Heterocyclic GPR40 modulators
AMGEN INC0 citations50
TULARIK INC
8 patentsUS6200995B1Mar 13, 2001
PPAR-γ modulators
TULARIK INC143 citations97
US6770648B2Aug 3, 2004
Compounds for the modulation of PPARγ activity
TULARIK INC39 citations96
US6583157B2Jun 24, 2003
Quinolinyl and benzothiazolyl modulators
TULARIK INC64 citations96
US6214880B1Apr 10, 2001
Arylsulfonanilide ureas
TULARIK INC38 citations96
US6620827B2Sep 16, 2003
PPARγ modulators
TULARIK INC36 citations91
US6583165B2Jun 24, 2003
Arylsulfonanilide ureas
TULARIK INC6 citations74
US6211167B1Apr 3, 2001
Arylsulfonanilide phosphates
TULARIK INC8 citations74
US6417176B2Jul 9, 2002
Arylsulfonanilide phosphates
TULARIK INC3 citations63